18.212.120.195
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Pediatrics

FDA approves digital therapeutic that uses TV shows to improve vision in children with lazy eye

Posted on October 20, 2021

The U.S. Food and Drug Administration has approved Luminopia One (Luminopia) as a prescription therapy to improve vision in children with amblyopia (lazy eye), the leading cause of vision loss in children, according to a company press release.

Luminopia One is indicated for improvement in visual acuity in children with amblyopia, aged 4-7, associated with anisometropia and/or with mild strabismus, having received treatment instructions as prescribed by a trained eye-care professional. Luminopia One allows patients to watch therapeutically modified TV shows and movies to improve their vision within a virtual reality (VR) headset. This is the first FDA-approved digital therapeutic for children with amblyopia, and more broadly, the first for a neuro-visual disorder.

Read the full press release here.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-